BP
BPTH.US Bio Path Holdings Inc
- Market cap
- USD 15.1K
- P/E
- -
- P/B
- 1.90x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2026.
Is BPTH.US undervalued?
Graham numberThe Graham number of Bio Path Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio Path Holdings Inc fundamental analysis
No fundamental analysis for Bio Path Holdings Inc yet.
Bio Path Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company'…
Full company profileBio Path Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bio Path Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 13.0K | 37.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -202K | 13.0K | 37.0K | -426K | -230K | -151K | -161K | -178K | -178K | - | - |
| Operating Income | -5.48M | -8.48M | -8.97M | -8.59M | -8.69M | -10.9M | -10.4M | -13.9M | -15.8M | -12.0M | -8.59M |
| EBITDA | -5.28M | -9.98M | -10.5M | -6.95M | -8.46M | -10.7M | -10.3M | -13.7M | -15.8M | -11.8M | -8.41M |
| Net Income | -5.47M | -6.75M | -7.02M | -8.58M | -8.51M | -10.9M | -10.4M | -13.8M | -16.1M | -9.89M | -8.70M |
| EPS | -12 | -15 | -14 | -14 | -64 | -56 | -31 | -38 | -34 | -1.72 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 10.8M | 12.2M | 8.86M | 2.34M | 22.7M | 16.5M | 26.6M | 16.0M | 3.22M | 3.88M | 677K |
| Total Liabilities | 937K | 3.96M | 791K | 1.12M | 1.57M | 1.41M | 1.11M | 1.80M | 2.78M | 3.73M | 9.16M |
| Shareholders' Equity | 9.82M | 8.24M | 8.07M | 1.22M | 21.1M | 15.1M | 25.5M | 14.2M | 441K | 154K | -8.49M |
| Cash & Short-term Investments | 8.85M | 9.38M | 5.97M | 1.00M | 20.4M | 13.8M | 23.8M | 10.4M | 1.05M | 1.17M | 12.0K |
| Total Debt | - | - | - | - | 415K | 330K | 235K | 221K | 113K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.00M | -8.15M | -7.96M | -6.12M | -8.36M | -11.0M | -9.92M | -15.1M | -11.5M | -10.6M | -1.63M |
| Capital Expenditure | 338K | 338K | 538K | 17.0K | 70.0K | 70.0K | 70.0K | 21.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.00M | -8.49M | -8.50M | -6.14M | -8.36M | -11.0M | -9.99M | -15.1M | -11.5M | -10.6M | -1.63M |
| Ratios | |||||||||||
| ROE | -55.7% | -81.9% | -87.1% | -704.7% | -40.3% | -72.0% | -41.0% | -97.6% | -3,645.8% | -6,424.7% | - |
| ROA | -50.8% | -55.3% | -79.3% | -367.6% | -37.5% | -65.9% | -39.3% | -86.6% | -499.3% | -254.8% | -1,284.3% |
| Net Profit Margin | - | -51,923.1% | -18,981.1% | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.26x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bio Path Holdings Inc dividends
Bio Path Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Feb 23, 2024.
Who owns Bio Path Holdings Inc
- Insiders 0.00%
- Institutions 0.87%
- Public & others 99.13%
- Shares outstanding 50.3M
- Free float 50.3M
Top funds holding BPTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Institutional Extnd Mkt Idx Tr | 13.5K | 0.23% | 0.00% | Dec 2024 |
| Fidelity Extended Market Index | 12.0K | 0.21% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - NL | 550.00 | 0.01% | 0.00% | Dec 2024 |
| Fidelity Series Total Market Index | 485.00 | 0.01% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 436.00 | 0.01% | -1.58% | Dec 2024 |
| Northern Trust Extended Eq Market Idx | 305.00 | 0.01% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - L | 305.00 | 0.01% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T4 | 73.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T3 | 73.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 47.00 | 0.00% | 0.00% | Sep 2024 |
| State St US Ttl Mkt Indx SL Cl I | 45.00 | 0.00% | 0.00% | Jan 2025 |
| Northern Trust Wilshire 5000 | 13.00 | 0.00% | 0.00% | Dec 2024 |
| BNYM Mellon SL Market Completion UC1 | 12.00 | 0.00% | 0.00% | Dec 2024 |
| State St US Extended Mkt Indx NL Cl C | 9.00 | 0.00% | 0.00% | Jan 2025 |
| SSgA U.S. Total Market Index Strategy | 4.00 | 0.00% | +33.33% | Jun 2024 |
| BNYM Mellon NSL Mkt Completion Fund Inst | 2.00 | 0.00% | 0.00% | Dec 2024 |
| Blackstone Alternative Multi-Strategy I | 1.00 | 0.00% | 0.00% | Sep 2024 |
Top institutions holding BPTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Apollon Wealth Management, LLC | 14.9K | 0.26% | 0.00% | Dec 2024 |
| Geode Capital Management, LLC | 13.6K | 0.24% | +25.14% | Sep 2024 |
| Vanguard Group Inc | 13.5K | 0.23% | 0.00% | Dec 2024 |
| Citadel Advisors Llc | 10.9K | 0.19% | 0.00% | Sep 2024 |
| Tower Research Capital LLC | 3.37K | 0.06% | -9.70% | Sep 2024 |
| UBS Group AG | 2.86K | 0.05% | +232.48% | Sep 2024 |
| BlackRock Inc | 2.38K | 0.04% | 0.00% | Sep 2024 |
| Tradewinds Capital Management, LLC | 50.00 | 0.00% | 0.00% | Dec 2024 |
| Morgan Stanley - Brokerage Accounts | 35.00 | 0.00% | -50.00% | Sep 2024 |
| Bank of America Corp | 27.00 | 0.00% | -41.30% | Sep 2024 |
| Group One Trading, LP | 21.00 | 0.00% | 0.00% | Sep 2024 |
| Global Retirement Partners, LLC. | 4.00 | 0.00% | 0.00% | Dec 2024 |
| Hanson Mcclain Inc | 1.00 | 0.00% | 0.00% | Dec 2024 |
| Qube Research & Technologies | 0.00 | 0.00% | -100.00% | Sep 2024 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Sep 2024 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Sep 2024 |
Bio Path Holdings Inc company profile
- Company name
- Bio Path Holdings Inc
- Ticker
- BPTH.US
- Exchange
- USA Stocks
- Listed since
- Mar 4, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
- Phone
- 832 742 1357
- Website
- biopathholdings.com
About Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Bio Path Holdings Inc management
5- Dr. Douglas P. MorrisCo-Founder, Director of Investor Relations & Secretary · born 1956
- Mr. Vikram Paul Grover C.F.A., Esq.President, CEO, CFO & Director · born 1970
- Mr. Michael Hickey M.B.A.Member of Scientific Advisory Board & VP of Clinical Operations
- Mr. Anthony Price MBASenior Vice President of Finance, Accounting & Administration
- Dr. Ana Tari Ashizawa M.B.A., Ph.D.Senior Vice President of Research, Development & Clinical Design